Network Pharmacology, Molecular Docking Analysis and Molecular Dynamics Simulation of Scutellaria baicalensis in the Treatment of Liver Fibrosis

Traditional Chinese medicine (SB), one of the clinical firstline heat-clearing drugs, has obvious symptomatic advantages for hepatic fibrosis with dampness-heat stasis as its syndrome. We aim to predict and validate the potential mechanism of active ingredients against liver fibrosis more scientific...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design Vol. 30; no. 17; p. 1326
Main Authors Wang, Junrui, Wu, Zhuoqing, Chen, Xiaolei, Sun, Ying, Ma, Shuyao, Weng, Jingdan, Zhang, Yuxin, Dong, Keke, Shao, Jiangjuan, Zheng, Shizhong
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2024
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Traditional Chinese medicine (SB), one of the clinical firstline heat-clearing drugs, has obvious symptomatic advantages for hepatic fibrosis with dampness-heat stasis as its syndrome. We aim to predict and validate the potential mechanism of active ingredients against liver fibrosis more scientifically and effectively. The underlying mechanism of in inhibiting hepatic fibrosis was studied by applying network pharmacology, molecular docking and molecular dynamics simulation. Expression levels of markers in activated Hepatic Stellate Cells (HSC) after administration of three extracts were determined by Western blot and Real-time PCR, respectively, in order to verify the anti-fibrosis effect of the active ingredients Results: There are 164 common targets of drugs and diseases screened and 115 signaling pathways obtained, which were mainly associated with protein phosphorylation, senescence and negative regulation of the apoptotic process. Western blot and Real-time PCR showed that extracts could reduce the expression of HSC activation markers, and Oroxylin A had the strongest inhibitory effect on it. Molecular docking results showed that Oroxylin A had high binding activity to target proteins. Molecular dynamics simulation demonstrates promising stability of the Oroxylin A-AKT1 complex over the simulated MD time of 200 ns. active ingredients may inhibit HSC proliferation, reduce the generation of pro-inflammatory factors and block the anti-inflammatory effect of inflammatory signal transduction by inducing HSC apoptosis and senescence, thus achieving the effect of anti-fibrosis.
AbstractList Traditional Chinese medicine (SB), one of the clinical firstline heat-clearing drugs, has obvious symptomatic advantages for hepatic fibrosis with dampness-heat stasis as its syndrome. We aim to predict and validate the potential mechanism of active ingredients against liver fibrosis more scientifically and effectively. The underlying mechanism of in inhibiting hepatic fibrosis was studied by applying network pharmacology, molecular docking and molecular dynamics simulation. Expression levels of markers in activated Hepatic Stellate Cells (HSC) after administration of three extracts were determined by Western blot and Real-time PCR, respectively, in order to verify the anti-fibrosis effect of the active ingredients Results: There are 164 common targets of drugs and diseases screened and 115 signaling pathways obtained, which were mainly associated with protein phosphorylation, senescence and negative regulation of the apoptotic process. Western blot and Real-time PCR showed that extracts could reduce the expression of HSC activation markers, and Oroxylin A had the strongest inhibitory effect on it. Molecular docking results showed that Oroxylin A had high binding activity to target proteins. Molecular dynamics simulation demonstrates promising stability of the Oroxylin A-AKT1 complex over the simulated MD time of 200 ns. active ingredients may inhibit HSC proliferation, reduce the generation of pro-inflammatory factors and block the anti-inflammatory effect of inflammatory signal transduction by inducing HSC apoptosis and senescence, thus achieving the effect of anti-fibrosis.
Author Sun, Ying
Weng, Jingdan
Dong, Keke
Shao, Jiangjuan
Wu, Zhuoqing
Zheng, Shizhong
Zhang, Yuxin
Chen, Xiaolei
Ma, Shuyao
Wang, Junrui
Author_xml – sequence: 1
  givenname: Junrui
  orcidid: 0000-0002-3100-793X
  surname: Wang
  fullname: Wang, Junrui
  organization: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
– sequence: 2
  givenname: Zhuoqing
  surname: Wu
  fullname: Wu, Zhuoqing
  organization: Nanjing Foreign Language School, Nanjing, China
– sequence: 3
  givenname: Xiaolei
  surname: Chen
  fullname: Chen, Xiaolei
  organization: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
– sequence: 4
  givenname: Ying
  surname: Sun
  fullname: Sun, Ying
  organization: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
– sequence: 5
  givenname: Shuyao
  surname: Ma
  fullname: Ma, Shuyao
  organization: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
– sequence: 6
  givenname: Jingdan
  surname: Weng
  fullname: Weng, Jingdan
  organization: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
– sequence: 7
  givenname: Yuxin
  surname: Zhang
  fullname: Zhang, Yuxin
  organization: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
– sequence: 8
  givenname: Keke
  surname: Dong
  fullname: Dong, Keke
  organization: PharmaBlock Sciences (Nanjing), Inc, Nanjing, China
– sequence: 9
  givenname: Jiangjuan
  surname: Shao
  fullname: Shao, Jiangjuan
  organization: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
– sequence: 10
  givenname: Shizhong
  surname: Zheng
  fullname: Zheng, Shizhong
  organization: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38616754$$D View this record in MEDLINE/PubMed
BookMark eNpNkEtOwzAYhC0Eog-4AvKCJQHbcWJ7WRUKSOUhtayr347TmiZ25SSg3IIj0wqQWI00880sZoSOffAWoUtKrhkV_IZQmkqaUyaZEkRwxknKBFGEMHKEhlSKNOFM5gM0app3QihTlJ-iQSpzmouMD9HXs20_Q9zi1w3EGkyowrq_wk-hsqarIOLbYLbOr_HEQ9U3rsHgi_9x76F2psELV--N1gWPQ4kXpmtttQccYA3OQGX9oew8bjcWL6OFtra-PbBz92Ejnjkdwx45QyclVI09_9UxepvdLacPyfzl_nE6mSeaZ6RNMg4ElOJKM6KlyTQzhRKiAFWa1FKuKJWl4gVneSktACtSaaVgVmuSg-ZsjC5-dnedrm2x2kVXQ-xXf9ewbwn3a44
CitedBy_id crossref_primary_10_1016_j_jep_2024_118448
crossref_primary_10_1016_j_ejphar_2025_177522
ContentType Journal Article
Copyright Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Copyright_xml – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.2174/0113816128297074240327090020
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-4286
ExternalDocumentID 38616754
Genre Journal Article
GrantInformation_xml – fundername: National College Student Innovation and Entrepreneurship Training Program
  grantid: 202210315143Z
– fundername: National Natural Science Foundation of China
  grantid: 82274185, 82073914
GroupedDBID ---
.5.
0R~
29F
36B
4.4
53G
5GY
69Q
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AAEGP
ABEEF
ABJNI
ABMOS
ABUWG
ABVDF
ACGFO
ACGFS
ACITR
ACIWK
ACPRK
ACZAY
ADBBV
AENEX
AFHZU
AFKRA
AFRAH
AFUQM
AGJNZ
AGQPQ
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ANTIV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
FYUFA
GH2
HMCUK
HZ~
IPNFZ
KCGFV
KFI
M1P
NPM
O9-
P2P
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
Q2X
RIG
UKHRP
ID FETCH-LOGICAL-b450t-54a0a9949b20b8c5b2cd977da9fc3e149118f94d426f8eaa2d38e872ebb06ab42
IngestDate Mon Jul 21 06:02:28 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 17
Keywords liver fibrosis
Oroxylin A
molecular docking
Scutellaria baicalensis
network pharmacology
molecular dynamics simulation
Language English
License Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b450t-54a0a9949b20b8c5b2cd977da9fc3e149118f94d426f8eaa2d38e872ebb06ab42
ORCID 0000-0002-3100-793X
PMID 38616754
ParticipantIDs pubmed_primary_38616754
PublicationCentury 2000
PublicationDate 2024-01-01
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-01
  day: 01
PublicationDecade 2020
PublicationPlace United Arab Emirates
PublicationPlace_xml – name: United Arab Emirates
PublicationTitle Current pharmaceutical design
PublicationTitleAlternate Curr Pharm Des
PublicationYear 2024
SSID ssj0012914
Score 2.437043
Snippet Traditional Chinese medicine (SB), one of the clinical firstline heat-clearing drugs, has obvious symptomatic advantages for hepatic fibrosis with...
SourceID pubmed
SourceType Index Database
StartPage 1326
SubjectTerms Animals
Humans
Liver Cirrhosis - drug therapy
Liver Cirrhosis - metabolism
Liver Cirrhosis - pathology
Medicine, Chinese Traditional
Molecular Docking Simulation
Molecular Dynamics Simulation
Network Pharmacology
Plant Extracts - chemistry
Plant Extracts - isolation & purification
Plant Extracts - pharmacology
Scutellaria baicalensis - chemistry
Title Network Pharmacology, Molecular Docking Analysis and Molecular Dynamics Simulation of Scutellaria baicalensis in the Treatment of Liver Fibrosis
URI https://www.ncbi.nlm.nih.gov/pubmed/38616754
Volume 30
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LatwwFBWTFkI2oe9XWrQI2cy49diybC1DaQiBhEImdLoKepmYEM-0Hi_Sr8gn5dN6JUu2JqTPjTGSbGzfw_U99yWEduPS9Lws04hmkkckJywC3NAoM41AMiZVZgPtxyf08IwczbP5aHQbZC21K_Fe_ri3ruR_pApjIFdTJfsPku1vCgNwDvKFI0gYjn8l45Muh3v8eeg_bb_Zsd_zFuxjeWkdH773iM2rGKa7_eib8Wl15fbxslUssjXFJUCj-VhwI0aT5t74nMhZn5xuAgwmsWN8AKx70VRNaOv61k_LizW3uVrLGfni_NVHbf29rfrR1gZNLtrFN_9rtSkInY6cVxzeoF982trRr36l82EkJPBh6E7vFnkaAROioWJ2ARsHwDxQs0Ch6X363_ArW9MwNfHQqYkS54b8kzhN8pgZ2zi8DKS5vLLYSAs6BepE_jx7pzu3n9pAG8BTzMarxlvkolgJm5JNtOse7MPvHmsLbfpb3SE41tCZPULbjqHg_Q5uj9FI10_QnoPY9QTPhoq9ZoL3cAi-p-jGYXJteIJ7yGGHSOwRiQGR4bRDJB4QiRclDhCJA0TiqsaASNwj0qy1iMQekc_Q2cGn2cfDyO36EQmSxasoIzzmjBEmklgUMhOJVEBSFGelTDUQeqDEJSMKTMuy0JwnKi10kSdaiJhyQZLn6EG9qPVLhKkQaUwU1aVWcF1SKNNXX5SSyzyVjL9CL7ovfb7sWrucexm8_uXMG7Q1IHgHPSxBl-i3YJiuxDsr_Z-y45Bv
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Network+Pharmacology%2C+Molecular+Docking+Analysis+and+Molecular+Dynamics+Simulation+of+Scutellaria+baicalensis+in+the+Treatment+of+Liver+Fibrosis&rft.jtitle=Current+pharmaceutical+design&rft.au=Wang%2C+Junrui&rft.au=Wu%2C+Zhuoqing&rft.au=Chen%2C+Xiaolei&rft.au=Sun%2C+Ying&rft.date=2024-01-01&rft.eissn=1873-4286&rft.volume=30&rft.issue=17&rft.spage=1326&rft_id=info:doi/10.2174%2F0113816128297074240327090020&rft_id=info%3Apmid%2F38616754&rft_id=info%3Apmid%2F38616754&rft.externalDocID=38616754